Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat…
Independent Study Shows Cue Health’s Molecular COVID-19 Test is as Accurate as Lab-Based PCR Test
SAN DIEGO, Calif., Aug. 17, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (NASDAQ: HLTH) announced today the preprint publication of an independent clinical study - the largest of itsSAN DIEGO, Calif., Aug. 17, 2022 /PRNewswire/ -- Cue Health Inc.
This Analyst Cuts I-Mab’s Price Target By 43%
I-Mab (NASDAQ: IMAB) reported significant changes to the company's collaboration on developing CD47 targeting agents.
Bluebird’s Gene Therapy Scores US Approval For Genetic Blood Disorder, Probably The Most Expensive
The FDA has approved Bluebird bio Inc’s (NASDAQ:BLUE) Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed for…
Analyst Sees Deteriorated Treatment Effect Of Blueprint’s Much Awaited Mastocytosis Data
Earlier today, Blueprint Medicines Corporation (NASDAQ: BPMC) released the long-awaited pivotal PIONEER dataset in Indolent Systemic Mastocytosis (ISM). The topline data indicates that…
Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022
As the U.S. plans to get out of the crisis phase, the Biden administration said it would stop buying…
Bluebird Bio Announces U.S. Commercial Infrastructure To Enable Patient Access To ZYNTEGLO
Price of ZYNTEGLO reflects potentially curative clinical benefit through achievement of durable transfusion independence and normal or near normal total hemoglobin levels
Innovative outcomes-based contract offering
Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial
Sanofi SA (NASDAQ:SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5…
Bluebird Bio PR Announces FDA Approval Of ZYNTEGLO
ZYNTEGLO offers potentially curative benefit across ages and genotypes, through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels
Management team to host conference